5 Top Pharmaceutical ETFs

五大医药类交易所交易基金分析:Invesco Dynamic资产价值最高

2019-05-15 22:30:00 Investing News Network

本文共2105个字,阅读需6分钟

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds as a way to stay informed about what companies are leading the industry. Pharma ETFs are key for investors who want to trade in a set of assets instead of individual companies. For novice investors, ETFs are composed of numerous companies in a specified industry. Advantages of ETF investments include gaining exposure to an overarching sector but still being able to trade it like a stock, less market volatility and lower fees and expenses. The pharma ETFs on this list have a broad portfolio of pharma companies in their holdings. Pharmaceutical ETFs give investors a broad view of what these companies have to offer and where they stand in the market. To help investors become more aware of what some of their options are when looking at investing in the pharmaceutical sector, the Investing News Network (INN) is looking at the five top ETFs (barring any leveraged ETFs) in the space, according to ETF Database. Included on the list are: The funds are arranged by the value of their assets. Here’s a closer look at these top pharmaceutical ETFs. 1. Invesco Dynamic Pharmaceuticals ETF The Invesco Dynamic Pharmaceuticals ETF is primarily focused on giving investors exposure to US-based pharmaceutical companies. Its analyst report says that this ETF chooses the individual securities on certain investment criteria, namely stock valuation and risk factors. Notably, it claims that investing in pharmaceutical companies can be risky due to US Food and Drug Administration (FDA) regulations and the “rigorous testing” required before a product hits the market. This ETF was started on June 23, 2005, and currently tracks 30 holdings. The top holdings this fund tracks are pharma giants such as Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), Merck (NYSE:MRK), Pfizer (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY), all weighing close to or over five percent each. 2. iShares US Pharmaceuticals ETF Created on May 5, 2006, the iShares US Pharmaceuticals ETF also tracks some of the top US pharma companies. In total, this ETF tracks 45 holdings with a market cap breakdown of 64 percent being large cap, 20 percent mid cap and 15 percent divided between micro cap and small cap. Its top holdings include Johnson & Johnson and Pfizer, each with over 20 percent weighting, Elanco Animal Health (NYSE:ELAN) with over five percent weightage, Zoetis (NYSE:ZTS) with a 4.65 percent weightage and Merck with a 4.28 percent weightage. 3. SPDR S&P Pharmaceuticals ETF The SPDR S&P Pharmaceuticals ETF came into the markets on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. The ETF’s analyst report suggests that, due to its narrow focus — which includes pharma giants that post “big returns” during times of consolidation — it should not be considered for a long-term investment portfolio. While this pharma ETF tracks 41 holdings, the fund’s top five ones all hover around the five percent mark, including Zoetis, Elanco Animal Heath, Perrigo Company (NYSE:PRGO), Jazz Pharmaceuticals (NASDAQ:JAZZ) and Johnson & Johnson. 4. VanEck Vectors Pharmaceutical ETF Established in late 2011, the VanEck Vectors Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index and has the capacity to provide big returns, even though there are some risks attached to the ETF. Its analyst report indicates investors looking for “tactical exposure” to the pharma sector might consider this ETF as an investment option. On this ETF are a slightly smaller 25 holdings, including top holdings such as McKesson (NYSE:MCK), Johnson & Johnson, AbbVie (NYSE:ABBV), GlaxoSmithKline (NYSE:GSK), Pfizer and Zoetis, all with over five percent weighting each. 5. KraneShares MSCI All China Health Care Index ETF The KraneShares MSCI All China Health Care Index ETF, begun on February 1, 2018, represents a market of pharmaceutical companies based in China. According to KraneShare, China has the fastest growing healthcare market in the world. This index tracks the most companies out of all the other ETFs at 59 holdings. Rounding out the fund’s top five holdings are Jiangsu Hengrui Medicine (SHA:600276), CSPC Pharmaceutical Group (HKG:1093), Sino Biopharmaceutical (HKG:1177), Wuxi Biologics Cayman (HKG:2269) and SinoPharm Group (HKG:1099).
经验丰富和新手投资者都可能希望将医药交易所交易基金( Pharmaceutical Exchange-trading funds )视为一种方式,让人们了解哪些公司在行业中处于领先地位。 对于想要交易一组资产而不是单个公司的投资者来说,医药 ETF 是关键。 对于新手投资者而言, ETF 由特定行业的众多公司组成。ETF 投资的优势包括获得对整个行业的敞口,但仍能像股票那样交易,降低市场波动性,降低费用和支出。 这份名单上的医药交易所交易基金持有的医药公司广泛的投资组合。医药 ETF 让投资者对这些公司必须提供的产品以及它们在市场上的地位有了广泛的了解。 ETF 数据库显示,为了帮助投资者更清楚地了解他们在投资医药行业时的一些选择,投资新闻网络( INN )正在研究这一领域的五大 ETF (杠杆 ETF 除外)。名单包括: 资金按其资产价值安排。下面是对这些顶级医药 ETF 的更深入研究。 1。Invesco Dynamic Pharmaceuticals ETF Invesco Dynamic Pharmaceuticals ETF 主要专注于让投资者接触美国制药公司。其分析师报告称,这只 ETF 根据特定的投资标准,即股票估值和风险因素,来选择个别证券。值得注意的是,该公司声称,由于美国食品药品监督管理局( FDA )的法规以及产品上市前所需的“严格检测”,投资制药公司可能存在风险。 这只 ETF 始于2005年6月23日,目前追踪30只股票。该基金跟踪的最大持股是强生公司( NYSE : JNJ )、雅培(Abbott)公司( NYSE : ABT )、默克(Merck)公司( NYSE : MRK )、辉瑞(Pfizer)公司( NYSE : PFE )和礼来(Eli Lilly)公司( NYSE : LLY )等医药巨头,它们的权重都接近或超过5%。 2。iShares 美国医药 ETF 创立于2006年5月5日的 iShares 美国医药交易所交易基金( iShares US Pharmaceuticals ETF )也追踪了一些美国顶级制药公司。总体而言,这只 ETF 追踪45只股票,市值下跌64%为大盘,20%为中盘,15%为微盘股和小盘股。 它的主要资产包括强生公司和辉瑞(Pfizer)公司,它们各自拥有超过20%的权重, Elanco 动物健康公司( NYSE : ELAN )拥有超过5%的权重, Zoetis ( NYSE : ZTS )拥有4.65%的权重,默克(Merck)拥有4.28%的权重。 3。SPDR S & P Pharmaceuticals ETF SPDR S & P Pharmaceuticals ETF 于2006年6月19日进入市场,代表 S & P Total Markets Index 旗下医药细分行业板块。ETF 的分析师报告显示,由于其关注范围狭窄(包括在整合期间发布“巨额回报”的制药巨头),不应将其视为长期投资组合。 虽然这只医药 ETF 追踪了41只股票,但该基金前五名的股票都徘徊在5%的关口附近,包括 Zoetis 、 Elanco Animal Heath 、 Perrigo Company ( NYSE : PRGO )、 Jazz Pharmaceuticals ( NASDAQ : JAZZ )和强生(Johnson & Johnson)。 4。VanEck Vectors Pharmaceutical ETF VanEck Vectors Pharmaceutical ETF 成立于2011年末,追踪 MVIS 美国上市医药25指数,并有能力提供高额回报,尽管该 ETF 存在一些风险。该公司的分析师报告显示,寻求医药行业“战术敞口”的投资者可能会将这只 ETF 视为一种投资选择。 在这只 ETF 上,持有的25只股票略少一些,其中包括麦肯森( NYSE : MCK )、强生( Johnson & Johnson )、艾伯维( AbbVie )( NYSE : ABBV )、葛兰素史克( GlaxoSmithKline , NYSE :葛兰素史克(GSK))、辉瑞( Pfizer )和 Zoetis 等最大的股票,它们的权重均超过5%。 5。KraneShares MSCI 明晟全中国医疗指数 ETF 2018年2月1日开始的 KraneShares MSCI All China Health Care Index ETF 代表了中国医药企业的一个市场。根据 KraneShare 的数据,中国拥有全球增长最快的医疗市场。 该指数追踪了所有其他 ETF 中59只股票中的大多数公司。基金前五名控股股东为江苏恒瑞医药( SHA :600276)、 CSPC 医药集团( HKG :1093)、 Sino Biopharma ( HKG :1177)、无锡 Biologics Cayman ( HKG :2269)及 SinoPharm Group ( HKG :1099)。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文